Urso Forte

AbbVie is a global, research-driven biopharmaceutical company that focuses on developing innovative medicines for some of the world's most complex and critical health conditions. Formed in 2013 as a spin-off from Abbott Laboratories, the company has established a dominant position in immunology with its flagship product Humira, as well as newer therapies like Skyrizi and Rinvoq. AbbVie significantly expanded its portfolio through the 2020 acquisition of Allergan, adding leading positions in aesthetics, eye care, and neuroscience. Among its diverse offerings is Urso Forte (ursodiol), a specialized treatment for primary biliary cholangitis. The company maintains a robust pipeline across oncology, virology, and gastroenterology, supported by extensive global manufacturing and R&D capabilities. AbbVie is headquartered in North Chicago, Illinois, and is publicly traded on the New York Stock Exchange.